CARIBOU BIOSCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.71 USD | -1.33% |
|
-3.64% | -35.25% |
| 05/04 | Sector Update: Health Care Stocks Lean Higher Pre-Bell Friday | MT |
| 04/04 | Caribou Gets FDA Clearance For Phase 1 Testing of CB-010 Cell Therapy in Lupus Patients | MT |
| Sales 2024 * | 9.54M 796M | Sales 2025 * | 9.73M 811M | Capitalization | 335M 27.94B |
|---|---|---|---|---|---|
| Net income 2024 * | -157M -13.09B | Net income 2025 * | -207M -17.26B | EV / Sales 2024 * | 35.1 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 34.5 x |
| P/E ratio 2024 * |
-2.08
x | P/E ratio 2025 * |
-1.79
x | Employees | 158 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.86% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | -1.33% | ||
| 1 week | -3.64% | ||
| Current month | -27.82% | ||
| 1 month | -27.54% | ||
| 3 months | -32.05% | ||
| 6 months | +1.37% | ||
| Current year | -35.25% |
1 week
3.69
4.21
1 month
3.695.15
Current year
3.698.33
1 year
3.448.59
3 years
3.4432.65
5 years
3.4432.65
10 years
3.4432.65
| Managers | Title | Age | Since |
|---|---|---|---|
Rachel Haurwitz
FOU | Founder | 38 | 28/11/28 |
Jason O’Byrne
DFI | Director of Finance/CFO | 54 | 09/21/09 |
Steven Kanner
CTO | Chief Tech/Sci/R&D Officer | 65 | 01/17/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 55 | 01/21/01 | |
Scott Braunstein
BRD | Director/Board Member | 60 | 01/21/01 |
| Director/Board Member | 59 | 08/21/08 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 6.97% | 2 M€ | -25.75% | ||
| 0.61% | 16 M€ | -8.49% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 3.71 | -1.33% | 1,044,964 |
| 25/24/25 | 3.76 | -2.34% | 1,632,852 |
| 24/24/24 | 3.85 | -3.27% | 1,079,741 |
| 23/24/23 | 3.98 | -0.25% | 930,742 |
| 22/24/22 | 3.99 | +3.64% | 1,384,845 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotes
Caribou Biosciences, Inc. is a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It is engaged in developing transformative therapies for patients with devastating diseases. Its genome-editing platform, including its Cas12a chRDNA technology, enables precision to develop cell therapies that are armored to potentially improve antitumor activity. Its pipeline includes three clinical-stage allogeneic cell therapies from its chimeric antigen receptor (CAR)-T (CAR-T) cell platform targeting the treatment of hematologic malignancies. CB-010 is the lead product candidate from its allogeneic CAR-T cell therapy platform and is being evaluated in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). Its second product candidate, CB-011, is being evaluated in patients with relapsed or refractory multiple myeloma (r/r MM) in the CaMMouflage phase I trial. CB-012 is its third product candidate.
Calendar
07/05/2024
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
3.71
USD
Average target price
20
USD
Spread / Average Target
+439.08%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -35.25% | 335M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- CRBU Stock
